Pathology Analysis & Statistics, September 2014 (p2)

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Publishers

All regions

You might be interested in: cancer, breast cancer, leukemia, more »

31-80 of about 4 100 reports

Purchase Reports From Reputable Market Research Publishers

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, China, United Kingdom, Europe
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Flovent (Asthma) - Forecast and Market Analysis to 2023

Flovent (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flovent (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Dulera (Asthma) - Forecast and Market Analysis to 2023

Dulera (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dulera (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dulera (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : World, United States
Fostair (Asthma) - Forecast and Market Analysis to 2023

Fostair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fostair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fostair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, World, United Kingdom, Europe
Xolair (Asthma) - Forecast and Market Analysis to 2023

Xolair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Xolair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Spiriva (Asthma) - Forecast and Market Analysis to 2023

Spiriva (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Spiriva (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Japan, Australia, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosatria (Mepolizumab) (Asthma) - Forecast and Market ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Benralizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Benralizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Benralizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Dupilumab (Asthma) - Forecast and Market Analysis to 2023

Dupilumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dupilumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dupilumab (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Quilizumab (Asthma) - Forecast and Market Analysis to 2023

Quilizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Quilizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quilizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tralokinumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
About 40 000 reports

Download Unlimited Documents from Trusted Public Sources

Janssen - Company Report, October 2014

  • Imbruvica® (ibrutinib) Supplemental New Drug Application Submit...
  • October 2014
    4 pages
  • Pathology  

  • United States  

View report >

About 100 Companies

Read our Company Profiles

Novartis Inc.

Switzerland

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

C.R. Bard Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.